These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 15546199

  • 1. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
    Gunaseelan S, Debrah O, Wan L, Leibowitz MJ, Rabson AB, Stein S, Sinko PJ.
    Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
    [Abstract] [Full Text] [Related]

  • 2. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
    Gaucher B, Rouquayrol M, Roche D, Greiner J, Aubertin AM, Vierling P.
    Org Biomol Chem; 2004 Feb 07; 2(3):345-57. PubMed ID: 14747863
    [Abstract] [Full Text] [Related]

  • 3. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
    Jain R, Agarwal S, Majumdar S, Zhu X, Pal D, Mitra AK.
    Int J Pharm; 2005 Oct 13; 303(1-2):8-19. PubMed ID: 16137847
    [Abstract] [Full Text] [Related]

  • 4. Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine).
    Li W, Chang Y, Zhan P, Zhang N, Liu X, Pannecouque C, De Clercq E.
    ChemMedChem; 2010 Nov 08; 5(11):1893-8. PubMed ID: 20936623
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and in vitro biological evaluation of mannose-containing prodrugs derived from clinically used HIV-protease inhibitors with improved transepithelial transport.
    Roche D, Greiner J, Aubertin AM, Vierling P.
    Bioconjug Chem; 2006 Nov 08; 17(6):1568-81. PubMed ID: 17105238
    [Abstract] [Full Text] [Related]

  • 6. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
    Andersson L, Davies J, Duncan R, Ferruti P, Ford J, Kneller S, Mendichi R, Pasut G, Schiavon O, Summerford C, Tirk A, Veronese FM, Vincenzi V, Wu G.
    Biomacromolecules; 2005 Nov 08; 6(2):914-26. PubMed ID: 15762660
    [Abstract] [Full Text] [Related]

  • 7. Peptide-poly(L-lysine citramide) conjugates and their in vitro anti-HIV behavior.
    Couffin-Hoarau AC, Aubertin AM, Boustta M, Schmidt S, Fehrentz JA, Martinez J, Vert M.
    Biomacromolecules; 2009 Apr 13; 10(4):865-76. PubMed ID: 19296658
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
    Roche D, Greiner J, Aubertin AM, Vierling P.
    Eur J Med Chem; 2008 Jul 13; 43(7):1506-18. PubMed ID: 17950955
    [Abstract] [Full Text] [Related]

  • 9. Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects.
    Wan L, Zhang X, Gunaseelan S, Pooyan S, Debrah O, Leibowitz MJ, Rabson AB, Stein S, Sinko PJ.
    AIDS Res Ther; 2006 Apr 24; 3():12. PubMed ID: 16635263
    [Abstract] [Full Text] [Related]

  • 10. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.
    Jain R, Duvvuri S, Kansara V, Mandava NK, Mitra AK.
    Int J Pharm; 2007 May 24; 336(2):233-40. PubMed ID: 17207946
    [Abstract] [Full Text] [Related]

  • 11. Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity.
    Santos C, Morais J, Gouveia L, de Clercq E, Pannecouque C, Nielsen CU, Steffansen B, Moreira R, Gomes P.
    ChemMedChem; 2008 Jun 24; 3(6):970-8. PubMed ID: 18389514
    [Abstract] [Full Text] [Related]

  • 12. Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir.
    Wang Z, Pal D, Mitra AK.
    J Pharm Sci; 2012 Sep 24; 101(9):3199-213. PubMed ID: 22611042
    [Abstract] [Full Text] [Related]

  • 13. Utility of poly(ethylene glycol) conjugation to create prodrugs of amphotericin B.
    Conover CD, Zhao H, Longley CB, Shum KL, Greenwald RB.
    Bioconjug Chem; 2003 Sep 24; 14(3):661-6. PubMed ID: 12757392
    [Abstract] [Full Text] [Related]

  • 14. Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide.
    Ramanathan S, Qiu B, Pooyan S, Zhang G, Stein S, Leibowitz MJ, Sinko PJ.
    J Control Release; 2001 Dec 13; 77(3):199-212. PubMed ID: 11733088
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May 13; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

  • 16. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds.
    Greenwald RB, Pendri A, Conover CD, Zhao H, Choe YH, Martinez A, Shum K, Guan S.
    J Med Chem; 1999 Sep 09; 42(18):3657-67. PubMed ID: 10479297
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J, HIV-NAT 017 Study Team.
    Antivir Ther; 2009 Sep 09; 14(2):241-8. PubMed ID: 19430099
    [Abstract] [Full Text] [Related]

  • 18. Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux.
    Jain R, Agarwal S, Mandava NK, Sheng Y, Mitra AK.
    Int J Pharm; 2008 Oct 01; 362(1-2):44-51. PubMed ID: 18620036
    [Abstract] [Full Text] [Related]

  • 19. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L, de Mendoza C, Soriano V.
    J Med Virol; 2005 Dec 01; 77(4):460-4. PubMed ID: 16254964
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K, Study Team.
    HIV Med; 2007 Nov 01; 8(8):529-35. PubMed ID: 17944686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.